Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients

Bibliography

• Dornbusch HJ, Manzoni P, Roilides E, et al. Invasive fungal infections in children. Pediatr Infect Dis J 2009;28(8):734-7
   PubMed Web of Science ®Google Scholar
• Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014;15(8):e327-40
   PubMed Web of Science ®Google Scholar
• Hundalani S, Pammi M. Invasive fungal infections in newborns and current management strategies. Expert Rev Anti Infect Ther 2013;11(7):709-21
   PubMed Web of Science ®Google Scholar
• Hope WW, Castagnola E, Groll AH, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012;18(Suppl 7):38-52
   PubMed Web of Science ®Google Scholar
• Arendrup MC. Update on antifungal resistance in Aspergillus and Candida. Clin Microbiol Infect 2014;20(Suppl 6):42-8
   PubMed Web of Science ®Google Scholar
• Tseng HK, Perfect JR. Strategies to manage antifungal drug resistance. Expert Opin Pharmacother 2011;12(2):241-56
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol 2008;25(2):101-6
   PubMed Web of Science ®Google Scholar
• Xie JL, Polvi EJ, Shekhar-Guturja T, et al. Elucidating drug resistance in human fungal pathogens. Future Microbiol 2014;9(4):523-42
   PubMed Web of Science ®Google Scholar
• Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol 2012;2012:713687
   PubMedGoogle Scholar
• Alcazar-Fuoli L, Mellado E. Current status of antifungal resistance and its impact on clinical practice. Br J Haematol 2014;166(4):471-84
   PubMed Web of Science ®Google Scholar
• Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008;5(11):e219
   PubMed Web of Science ®Google Scholar
• van der Linden JW, Snelders E, Kampinga GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 2011;17(10):1846-54
   PubMed Web of Science ®Google Scholar
• Kathiravan MK, Salake AB, Chothe AS, et al. The biology and chemistry of antifungal agents: a review. Bioorg Med Chem 2012;20(19):5678-98
   PubMed Web of Science ®Google Scholar
• Prasad R, Rawal MK. Efflux pump proteins in antifungal resistance. Front Pharmacol 2014;5:202
   PubMed Web of Science ®Google Scholar
• Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012;125(1 Suppl):S3-13
   PubMed Web of Science ®Google Scholar
• Morio F, Loge C, Besse B, et al. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagn Microbiol Infect Dis 2010;66(4):373-84
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12(4):501-17
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Sharma C, Hagen F, et al. Exploring azole antifungal drug resistance in Aspergillus fumigatus with special reference to resistance mechanisms. Future Microbiol 2014;9(5):697-711
   PubMed Web of Science ®Google Scholar
• van Ingen J, van der Lee HA, Rijs TA, et al. Azole, polyene and echinocandin MIC distributions for wild-type, TR34/L98H and TR46/Y121F/T289A Aspergillus fumigatus isolates in the Netherlands. J Antimicrob Chemother 2015;70(1):178-81
   PubMed Web of Science ®Google Scholar
• Autmizguine J, Guptill JT, Cohen-Wolkowiez M, et al. Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications. Drugs 2014;74(8):891-909
   PubMed Web of Science ®Google Scholar
• Stockmann C, Constance JE, Roberts JK, et al. Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. Clin Pharmacokinet 2014;53(5):429-54
   PubMed Web of Science ®Google Scholar
• Finco G, Sanna D, Evangelista M, et al. Fungal infections in pediatric intensive care units. J Matern Fetal Neonatal Med 2011;24(Suppl 2):21-3
   PubMedGoogle Scholar
• Maenza JR, Merz WG, Romagnoli MJ, et al. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis 1997;24(1):28-34
   PubMed Web of Science ®Google Scholar
• Brion LP, Uko SE, Goldman DL. Risk of resistance associated with fluconazole prophylaxis: systematic review. J Infect 2007;54(6):521-9
   PubMed Web of Science ®Google Scholar
• Melo NR, Taguchi H, Culhari VP, et al. Oral candidiasis of HIV-infected children undergoing sequential HIV therapies. Med Mycol 2009;47(2):149-56
   PubMed Web of Science ®Google Scholar
• Khan Z, Ahmad S, Joseph L, et al. Candida dubliniensis: an appraisal of its clinical significance as a bloodstream pathogen. PLoS One 2012;7(3):e32952
   Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48(5):503-35
   PubMed Web of Science ®Google Scholar
• Lestner JM, Versporten A, Doerholt K, et al. Systemic antifungal prescribing in neonates and children: outcomes from the antibiotic resistance and prescribing in European children (ARPEC) Study. Antimicrob Agents Chemother 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Patel K, Roberts JA, Lipman J, et al. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob Agents Chemother 2011;55(12):5868-73
   PubMed Web of Science ®Google Scholar
• Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008;52(11):4043-9
   PubMed Web of Science ®Google Scholar
• Ahmad S, Khan Z, Hagen F, et al. Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in Kuwait. Environ Res 2014;133:20-6
   PubMed Web of Science ®Google Scholar
• Castanheira M, Messer SA, Jones RN, et al. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. Int J Antimicrob Agents 2014;44:320-6
   PubMed Web of Science ®Google Scholar
• Verweij PE, Snelders E, Kema GH, et al. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? Lancet Infect Dis 2009;9(12):789-95
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327-60
   PubMed Web of Science ®Google Scholar
• NOXAFIL (posaconazole); highlights of prescribing information. Merck &Co
   Google Scholar
• Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 2014;20(Suppl 3):5-26
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Gamaletsou MN. Treatment of fungal disease in the setting of neutropenia. Hematology Am Soc Hematol Educ Program 2013;2013:423-7
   PubMed Web of Science ®Google Scholar
• Stan CD, Tuchilus C, Stan CI. Echinocandins--new antifungal agents. Rev Med Chir Soc Med Nat Iasi 2014;118(2):528-36
   PubMedGoogle Scholar
• Lockhart SR, Zimbeck AJ, Baddley JW, et al. In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network. Antimicrob Agents Chemother 2011;55(8):3944-6
   PubMed Web of Science ®Google Scholar
• Groll AH, Stergiopoulou T, Roilides E, et al. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin Investig Drugs 2005;14(4):489-509
   PubMed Web of Science ®Google Scholar
• Feldmesser M, Kress Y, Mednick A, et al. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000;182(6):1791-5
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008;46(1):120-8
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36(10):2950-6
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? Curr Opin Infect Dis 2014;27(6):484-92
   PubMed Web of Science ®Google Scholar
• Laverdiere M, Lalonde RG, Baril JG, et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006;57(4):705-8
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Espinel-Ingroff A, Bustamante B, et al. Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. Antimicrob Agents Chemother 2014;58(2):916-22
   PubMed Web of Science ®Google Scholar
• Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013;56(12):1724-32
   PubMed Web of Science ®Google Scholar
• Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 2006;50(6):2058-63
   PubMed Web of Science ®Google Scholar
• Assessment report for Mycamine. European Medicines Agency; London: 24 April 2008. Doc.Ref.: EMEA/CHMP/121708/2008
   Google Scholar
• Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008;197(1):163-71
   PubMed Web of Science ®Google Scholar
• Warn PA, Livermore J, Howard S, et al. Anidulafungin for neonatal hematogenous Candida meningoencephalitis: identification of candidate regimens for humans using a translational pharmacological approach. Antimicrob Agents Chemother 2012;56(2):708-14
   PubMed Web of Science ®Google Scholar
• Cornely OA, Vehreschild JJ, Vehreschild MJ, et al. Phase II dose escalation study of caspofungin for invasive Aspergillosis. Antimicrob Agents Chemother 2011;55(12):5798-803
   PubMed Web of Science ®Google Scholar
• Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009;48(12):1676-84
   PubMed Web of Science ®Google Scholar
• Loo AS, Muhsin SA, Walsh TJ. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B. Expert Opin Drug Saf 2013;12(6):881-95
   PubMed Web of Science ®Google Scholar
• Mesa-Arango AC, Trevijano-Contador N, Roman E, et al. The production of reactive oxygen species is an universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug: AMPHORES study. Antimicrob Agents Chemother 2014;58(11):6627-38
   PubMed Web of Science ®Google Scholar
• Ozsevik SN, Sensoy G, Karli A, et al. Invasive fungal infections in children with hematologic and malignant diseases. J Pediatr Hematol Oncol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Marr KA, Rex JH, et al. Amphotericin B: time for a new “gold standard”. Clin Infect Dis 2003;37(3):415-25
   PubMed Web of Science ®Google Scholar
• Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004;23(12):1093-7
   PubMed Web of Science ®Google Scholar
• Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50(6):2009-15
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Melcher GP, Rinaldi MG, et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990;28(7):1616-22
   PubMed Web of Science ®Google Scholar
• Sterling TR, Merz WG. Resistance to amphotericin B: emerging clinical and microbiological patterns. Drug Resist Updat 1998;1(3):161-5
   PubMed Web of Science ®Google Scholar
• Eddouzi J, Parker JE, Vale-Silva LA, et al. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals. Antimicrob Agents Chemother 2013;57(7):3182-93
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE, Tansarli GS. continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis. PLoS One 2013;8(10):e77075
   Web of Science ®Google Scholar
• Quinto-Alemany D, Canerina-Amaro A, Hernandez-Abad LG, et al. Yeasts acquire resistance secondary to antifungal drug treatment by adaptive mutagenesis. PLoS One 2012;7(7):e42279
   Web of Science ®Google Scholar
• Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother 2012;56(6):3107-13
   PubMed Web of Science ®Google Scholar
• Hope WW, Warn PA, Sharp A, et al. Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrob Agents Chemother 2006;50(11):3680-8
   PubMed Web of Science ®Google Scholar
• Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int 2013;2013:204237
   PubMed Web of Science ®Google Scholar
• Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46(2):171-9
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Overcoming antifungal resistance. Drug Discov Today Technol 2014;11:65-71
   PubMedGoogle Scholar
• DIFLUCAN (fluconazole); package insert. Revised 03/2014 by Pfizer Inc
   Google Scholar
• Piper L, Smith PB, Hornik CP, et al. Fluconazole loading dose pharmacokinetics and safety in infants. Pediatr Infect Dis J 2011;30(5):375-8
   PubMed Web of Science ®Google Scholar
• Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 1994;13(4):325-9
   PubMed Web of Science ®Google Scholar
• SPORANOX (itraconazole); package insert. Revised 01/2013 by JANSSEN-CILAG
   Google Scholar
• Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev 2010;11:CD003940
   Google Scholar
• Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002;46(8):2554-63
   PubMed Web of Science ®Google Scholar
• Schmitt C, Perel Y, Harousseau JL, et al. Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob Agents Chemother 2001;45(5):1561-4
   PubMed Web of Science ®Google Scholar
• de Repentigny L, Ratelle J, Leclerc JM, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998;42(2):404-8
   PubMed Web of Science ®Google Scholar
• VFEND (voriconazole); package insert. Revised 11/2010 by Pfizer Inc
   Google Scholar
• Friberg LE, Ravva P, Karlsson MO, et al. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother 2012;56(6):3032-42
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010;54(10):4116-23
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21(3):240-8
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004;48(6):2166-72
   PubMed Web of Science ®Google Scholar
• NOXAFIL, European Medicines Agency, EPAR: product information. Last updated 10/06/2014
   Google Scholar
• Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007;51(3):812-18
   PubMed Web of Science ®Google Scholar
• Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009;53(4):1450-6
   PubMed Web of Science ®Google Scholar
• Li CC, Sun P, Dong Y, et al. Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients. Antimicrob Agents Chemother 2011;55(5):2098-105
   PubMed Web of Science ®Google Scholar
• CANCIDAS: (caspofungin acetate): highlights for prescribing information. Revised 09/2014 by Merck &Co
   Google Scholar
• Saez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009;53(3):869-75
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005;49(11):4536-45
   PubMed Web of Science ®Google Scholar
• Ascher S, Smith PB, Benjamin DKJr. Safety of micafungin in infants: insights into optimal dosing. Expert Opin Drug Saf 2011;10(2):281-6
   PubMed Web of Science ®Google Scholar
• Emiroglu M. Micafungin use in children. Expert Rev Anti Infect Ther 2011;9(9):821-34
   PubMed Web of Science ®Google Scholar
• Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009;28(5):412-15
   PubMed Web of Science ®Google Scholar
• Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007;51(10):3714-19
   PubMed Web of Science ®Google Scholar
• MYCAMINE (micafungin sodium): Highlights of prescribing information. Revised: June 2013 by Astellas Pharma
   Google Scholar
• Cohen-Wolkowiez M, Benjamin DKJr, Piper L, et al. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates. Clin Pharmacol Ther 2011;89(5):702-7
   PubMed Web of Science ®Google Scholar
• Benjamin DKJr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006;50(2):632-8
   PubMed Web of Science ®Google Scholar
• FUNGIZONE (amphotericin B for Injection): package insert. Bristol-Myers Squibb; Canada
   Google Scholar
• Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr 1990;116(5):791-7
   PubMed Web of Science ®Google Scholar
• Benson JM, Nahata MC. Pharmacokinetics of amphotericin B in children. Antimicrob Agents Chemother 1989;33(11):1989-93
   PubMed Web of Science ®Google Scholar
• Nath CE, McLachlan AJ, Shaw PJ, et al. Population pharmacokinetics of amphotericin B in children with malignant diseases. Br J Clin Pharmacol 2001;52(6):671-80
   PubMed Web of Science ®Google Scholar
• AmBisome, (amphotericin B liposome for injection): package insert. revised 05/2012 Marketed by Astellas Pharma US, Inc. Manufactured by Gilead Sciences, Inc
   Google Scholar
• Walsh TJ, Whitcomb P, Piscitelli S, et al. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob Agents Chemother 1997;41(9):1944-8
   PubMed Web of Science ®Google Scholar
• Wurthwein G, Groll AH, Hempel G, et al. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother 2005;49(12):5092-8
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J 1999;18(8):702-8
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Smith PB, Mangum B, et al. Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. J Perinatol 2007;27(2):97-100
   PubMed Web of Science ®Google Scholar
• Hope WW, Warn PA, Sharp A, et al. Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing. Antimicrob Agents Chemother 2007;51(10):3760-2
   PubMed Web of Science ®Google Scholar
• Varisco BM, Benner KW, Prabhakaran P. Neonatal peritoneal candidiasis successfully treated with anidulafungin add-on therapy. Ann Pharmacother 2009;43(11):1907-10
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008;47(3):364-71
   PubMed Web of Science ®Google Scholar
• Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50(3):291-322
   PubMed Web of Science ®Google Scholar